跳至主要内容
临床试验/JPRN-jRCTs071180083
JPRN-jRCTs071180083进行中(未招募)1 期

Feasibility study of adjuvant chemotherapy with cisplatin(CDDP) and TS-1 in followed by alternate-day treatment with TS-1 in patients with completely resected pathological II-IIIA non small cell lung cancer - None

Suzuki Makoto0 个研究点目标入组 58 人开始时间: 2019年3月29日最近更新:

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
58

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 < 80age old(—)
性别
All

入选标准

  • 1) Pathologically confirmed diagnosis of NSCLC.
  • 2) Non-small cell lung cancer with stage II-IIIA
  • 3) Completely resected
  • 4) Oral intake
  • 5) LN dissection more than ND2a-1
  • 6) Neither previous chemotherapy nor radiotherapy before operation
  • 7) Performance Status (ECOG) 0-2
  • 8) Aged 20-75 years old
  • 9)Have adequate organ function within 14 days before study entry
  • a.Leukocyte count 3,000/mm3 or over
  • b.Granulocyte count 1,500/mm3 or over
  • c.Platelet count 100,000/mm3 or over
  • d.Hb 9.0 g/dl or over
  • e.AST(GOT) 2.5 x the Upper Limits of Normal(ULN) or under
  • f.ALT(GPT) 2.5 x the Upper Limits of Normal (ULN) or under
  • g.Total bilirubin 1.5 mg/dL or under
  • h.Serum creatinine 1.5 mg/dl or under
  • i. creatinine clearance 50 mL / min or over
  • j.PaO2 60torr or over or SpO2 90% or over
  • 10) Written informed consent to participate.
  • 11) Possible to receive chemotherapy within 8 week after surgery

排除标准

  • 1)Anamnesis of hypersensitivity to drugs
  • 2)Massive pleural or pericardial effusion
  • 3) With active double cancer
  • 4)Severe complication (ileus , interstitial pneumonia , interstitial pneumonia , pulmonary fibrosis, uncontrolled diabetes , heart failure , renal failure, hepatic failure, and so on)
  • 5) With active infections
  • 6) With a difficult bowel movement
  • 7) Pleural effusion, cardiac effusion, or cardiac effusion necessitating treatment.
  • 8) Pregnancy or lactating patients
  • 9) Uncontrolled psychiatric disease
  • 10)With poor-controlled diabetes mellitus
  • 11) Concurrent steroid therapy
  • 12) With HBs or HCV
  • 13) With HIV
  • 14) Physician judged improper to entry this trial

研究者

发起方
Suzuki Makoto

相似试验

已完成
不适用
Feasibility study of adjuvant chemotherapy with cisplatin and pemetrexed short hydration regimen for completely resected NSCLCCompletely resected NSCLC(non-squamous cell carcinoma, stage II - IIIA)
JPRN-UMIN000010336Division of Respiratory Medicine, Department of Internal Medicine,Kobe University Graduate School of Medicine21
招募中
不适用
Feasibility study of adjuvant chemotherapy with cisplatin(CDDP) and TS-1 in followed by alternate-day treatment with TS-1 in patients with completely resected pathological II-IIIA non small cell lung canceron-small cell lung cancer
JPRN-UMIN000011345Department of Thoracic Surgery , Faculty of Life Science Kumamoto University58
已完成
2 期
Feasibility study of adjuvant chemotherapy with combination Docetaxel AND Daily Oral Cyclophosphamide for Japanese breast cancer patients.Breast Cancer
JPRN-UMIN000006673Shiga University of Medical Science20
已完成
不适用
Feasibility study of adjuvant chemotherapy with carboplatin and nab-paclitaxel for resected NSCLCresected NSCLC(stage II - IIIB)
JPRN-UMIN000011910Division of Respiratory Medicine, Department of Internal Medicine,Kobe University Graduate School of Medicine21
招募中
不适用
Feasibility study of adjuvant chemotherapy with nanoparticle albumin-bound (nab)- paclitaxel and carboplatin in patients with completely resected pathological IB non small cell lung canceron-small cell lung cancer
JPRN-UMIN000011215Department of Thoracic Surgery , Faculty of Life Science Kumamoto University35